T1	No-of-participants 633 639	27 347
T2	eligibility 640 660	postmenopausal women
T3	average-age 666 685	50 through 79 years
T4	eligibility 686 755	with no prior breast cancer and negative baseline screening mammogram
T5	location 783 785	US
T6	duration 794 811	from 1993 to 1998
T7	No-of-participants 877 883	16 608
T8	intervention-participants 905 909	8506
T9	intervention 951 983	conjugated equine estrogen (CEE)
T10	control-participants 1039 1043	8102
T11	control 1045 1052	placebo
T12	No-of-participants 1077 1083	10 739
T13	intervention-participants 1115 1119	5310
T14	control-participants 1175 1179	5429
T15	outcome-Measure 1394 1417	breast cancer incidence
T16	outcome-Measure 1506 1562	deaths from breast cancer and deaths after breast cancer
T17	No-of-participants 1570 1576	27 347
T18	average-age 1658 1680	63.4 years [7.2 years]
T19	outcome 1926 1949	breast cancer incidence
T20	intervention-participants 1833 1839	10 739
T21	intervention-value 1955 1958	238
T22	intervention-value 1983 1988	0.30%
T23	control-value 1993 1996	296
T24	control-value 2021 2026	0.37%
T26	intervention-value 2169 2171	30
T27	intervention-value 2207 2213	0.031%
T28	control-value 2218 2220	46
T29	control-value 2256 2262	0.046%
T30	control-participants 2357 2363	16 608
T31	outcome 2439 2462	breast cancer incidence
T32	intervention-value 2468 2471	584
T33	intervention-value 2496 2501	0.45%
T34	control-value 2506 2509	447
T35	control-value 2534 2539	0.36%
T37	intervention-value 2642 2644	71
T38	intervention-value 2680 2686	0.045%
T39	control-value 2691 2693	53
T40	control-value 2729 2735	0.035%
T25	outcome 2140 2163	breast cancer mortality
T36	outcome 2613 2636	breast cancer mortality
